Latest news
CILcare won FACCNE’s 2023 Women in Business award!
CILcare’s team is honored to have been awarded by the French-American Chamber of New England (FACCNE) in the Women in Business category. The French-American Business Awards took place during FACCNE's annual gala, which has been celebrating for over 20 years the best...
CILcare announces the launch of the OrgaEar project with SATT AxLR and the University of Montpellier
Sylvie PUCHEU, CILcare’s Chief Scientific Officer and Philippe NERIN, SATT AxLR’s PresidentMontpellier - France – May 17th, 2023 – CILcare, a company specialized in the research and development of new therapies for auditory pathologies, and SATT AxLR are launching the...
CILCARE NOMINATED BY FACCNE FOR WOMEN IN BUSINESS AWARD 2023 !
CILcare’s team is honored and delighted to be part of the nominees for Women in Business Award by the French-American Chamber of New England (FACCNE). In one night only, FACCNE groups its Annual Gala and Awards Ceremony to recognize Excellence, Innovation and...
CILcare, a catalyzer for therapeutic development in auditory-related disorders
CILcare is a biotech company dedicated to harnessing its unique expertise in auditory sciences to enable the early and specific detection of neurocognitive and inflammatory diseases. CILcare’s proprietary pipeline focuses on synaptopathy, a disease affecting cochlear synapses and nerve fibers. Cochlear synaptopathy is clinically characterized by a lack of intelligibility in noisy environments, considered as the early signs of age-related hearing loss and aggravated by noise exposure.
Committed to its mission of accelerating the development of novel therapies for ear disorders, CILcare has built a unique smart R&D platform to offer external innovation to its partners. Based on an unmatched expertise in preclinical otology, CILcare has supported, worldwide, top hearing research companies, biotech, pharma and academic institutions in their various development stages.
With hearing labs established in Montpellier, France, and Lexington, MA, in partnership with CBSET, a biomedical translational research center, CILcare provides comprehensive preclinical programs including: drug screening on otic cell lines, cochlear explants studies, GLP-ototoxicity, inner ear pharmacokinetics, histology of the cochlea and vestibular systems, intra-cochlear deliveries, micro-surgery, micro-pump implantation, noise-induced, drug-induced, age-related, disease-related efficacy models in mice, rats, guinea pigs, tolerance and ototoxicity with state-of-the art auditory assessment with electrophysiology, electroacoustics and behavioral tests, gene transduction in the inner ear, transtympanic injections, cell grafts, …
Testimonials

Pharma / Biotech

Medtech

Nutraceutical

Veterinary
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect 2.5 billion people globally by 2050 according to the WHO. In 2019, 1.6 billion people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 1 trillion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.